BRIEF: Leading RNA drug developer Ribo passes Hong Kong listing hearing, kicking off IPO
Leading RNA drug developer Suzhou Ribo Life Science Co. Ltd. passed its hearing for a listing on the Hong Kong Stock Exchange, marking the official launch of its IPO, according…
RELATED ARTICLES
-
BRIEF: Butong passes listing hearing, targets IPO launch by month’s end
- BRIEF: Guoxia Technology clears Hong Kong listing hearing
- BRIEF: Nuobikan clears Hong Kong listing hearing
- Obesity drug maker Sciwind targets IPO, with heavyweight backers
-
BRIEF: Robot developer Yunji Tech to raise $85 million in Hong Kong IPO
2670.HK
-
CSPC feels the pain from sweeping cuts in drug prices
1093.HK
- Ming Yu seeks a share of the drug sector limelight
